Deuterium-enriched pioglitazone
The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
1. A deuterium-enriched compound
or a pharmaceutically acceptable salt thereof, wherein
R 1 and R 2 are independently selected from H and D, and R 3 -R 20 are H;
wherein the abundance of deuterium in R 1 is at least 30% and the abundance of deuterium in R 2 is at least 30%.
2. The deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 is at least 50% and the abundance of deuterium in R 2 is at least 50%.
3. The deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 is at least 50% and the abundance of deuterium in R 2 is at least 90%.
4. The deuterium-enriched compound of claim 1 , wherein R 1 is D.
5. A deuterium-enriched compound
or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently selected from H and D, and R 3 -R 20 are H;
wherein the abundance of deuterium in R 1 is at least 30% and the abundance of deuterium in R 2 is at least 90%.
6. The deuterium-enriched compound of claim 5 , wherein R 1 is H.
7. The deuterium-enriched compound of claim 5 , wherein R 1 is D.
8. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.